These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 23943401)
1. In vitro-in vivo correlation of efavirenz tablets using GastroPlus®. Honório Tda S; Pinto EC; Rocha HV; Esteves VS; dos Santos TC; Castro HC; Rodrigues CR; de Sousa VP; Cabral LM AAPS PharmSciTech; 2013 Sep; 14(3):1244-54. PubMed ID: 23943401 [TBL] [Abstract][Full Text] [Related]
2. Silva TMD; Honorio TDS; Chaves MHDC; Duque MD; Cabral LM; Patricio BFC; Rocha HVA Drug Dev Ind Pharm; 2021 Aug; 47(8):1342-1352. PubMed ID: 34622730 [TBL] [Abstract][Full Text] [Related]
3. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Kovacević I; Parojcić J; Homsek I; Tubić-Grozdanis M; Langguth P Mol Pharm; 2009; 6(1):40-7. PubMed ID: 19248231 [TBL] [Abstract][Full Text] [Related]
4. Developing in vitro-in vivo correlation of risperidone immediate release tablet. Saibi Y; Sato H; Tachiki H AAPS PharmSciTech; 2012 Sep; 13(3):890-5. PubMed ID: 22696224 [TBL] [Abstract][Full Text] [Related]
5. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation. Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538 [TBL] [Abstract][Full Text] [Related]
6. In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software. Wang L; Chen J; Chen W; Ruan Z; Lou H; Yang D; Jiang B BMC Pharmacol Toxicol; 2023 Nov; 24(1):69. PubMed ID: 38017512 [TBL] [Abstract][Full Text] [Related]
7. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Jantratid E; Prakongpan S; Amidon GL; Dressman JB Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285 [TBL] [Abstract][Full Text] [Related]
8. Prediction of plasma concentrations using in silico modelling and simulation approach: Case of Acebutolol. Bokri E; Felfel H; Bahri S Ann Pharm Fr; 2021 Sep; 79(5):530-538. PubMed ID: 33675740 [TBL] [Abstract][Full Text] [Related]
9. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model. Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663 [TBL] [Abstract][Full Text] [Related]
10. Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets. Ibarra M; Magallanes L; Lorier M; Vázquez M; Fagiolino P Eur J Pharm Sci; 2016 Mar; 85():106-11. PubMed ID: 26850681 [TBL] [Abstract][Full Text] [Related]
11. Characterization, Bedor DCG; Bedor NCTC; Neto JGP; José de Alencar Danda L; de Oliveira FM; de Oliveira GHO; Soares Sobrinho JL; Beyssac E; Castro WV; Santana DP Drug Dev Ind Pharm; 2021 May; 47(5):725-734. PubMed ID: 34038291 [TBL] [Abstract][Full Text] [Related]
12. Development of Pediatric Orodispersible Tablets Based on Efavirenz as a New Therapeutic Alternative. de Freitas Neto JL; do Nascimento Gomes Barbosa I; de Melo CG; Ângelos MA; Dos Santos Mendes LM; Ferreira MRA; Rolim LA; Soares LAL; da Silva RMF; Neto PJR Curr HIV Res; 2020; 18(5):342-353. PubMed ID: 32614748 [TBL] [Abstract][Full Text] [Related]
13. In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets. Yaro P; He X; Liu W; Xun M; Ma Y; Li Z; Shi X Drug Dev Ind Pharm; 2014 Dec; 40(12):1670-6. PubMed ID: 24102615 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of sex-by-formulation interaction in bioequivalence studies of efavirenz tablets. González-Rojano E; Abad-Santos F; Ochoa D; Román M; Marcotegui J; Álvarez C; Gordon J; García-Arieta A Br J Clin Pharmacol; 2018 Aug; 84(8):1729-1737. PubMed ID: 29633302 [TBL] [Abstract][Full Text] [Related]
15. Correlation between microstructure and bioequivalence in anti-HIV drug efavirenz. Fandaruff C; Segatto Silva MA; Galindo Bedor DC; de Santana DP; Rocha HV; Rebuffi L; Azanza Ricardo CL; Scardi P; Cuffini SL Eur J Pharm Biopharm; 2015 Apr; 91():52-8. PubMed ID: 25661587 [TBL] [Abstract][Full Text] [Related]
16. Impact of superdisintegrants on efavirenz release from tablet formulations. Rajesh YV; Balasubramaniam J; Bindu K; Sridevi R; Swetha M; Rao VU Acta Pharm; 2010 Jun; 60(2):185-95. PubMed ID: 21134855 [TBL] [Abstract][Full Text] [Related]
17. Mechanical activation of Efavirenz: the effects on the dissolution and inhibitory behavior. Cappelletto E; Firrito C; Pizzato M; Rebuffi L; Scardi P Pharm Dev Technol; 2018 Dec; 23(10):1128-1135. PubMed ID: 29688125 [TBL] [Abstract][Full Text] [Related]
18. Development of an In Vivo Predictive Dissolution Methodology of Topiroxostat Immediate-Release Tablet Using In Silico Simulation. Li G; Yang H; Liu W; Shen C; Ji Y; Sun Y; Huo Q; Liu Y; Wang G AAPS PharmSciTech; 2021 Apr; 22(3):132. PubMed ID: 33851275 [TBL] [Abstract][Full Text] [Related]
19. Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data. Mittapalli RK; Marroum P; Qiu Y; Apfelbaum K; Xiong H Pharm Res; 2017 Jul; 34(7):1527-1533. PubMed ID: 28512718 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in silico characterisation of Tacrolimus released under biorelevant conditions. Mercuri A; Wu S; Stranzinger S; Mohr S; Salar-Behzadi S; Bresciani M; Fröhlich E Int J Pharm; 2016 Dec; 515(1-2):271-280. PubMed ID: 27737809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]